EA201591123A1 - Комбинации агониста glp1r и метформина, а также способ их применения при лечении диабета 2 типа и прочих расстройств - Google Patents
Комбинации агониста glp1r и метформина, а также способ их применения при лечении диабета 2 типа и прочих расстройствInfo
- Publication number
- EA201591123A1 EA201591123A1 EA201591123A EA201591123A EA201591123A1 EA 201591123 A1 EA201591123 A1 EA 201591123A1 EA 201591123 A EA201591123 A EA 201591123A EA 201591123 A EA201591123 A EA 201591123A EA 201591123 A1 EA201591123 A1 EA 201591123A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- agonist
- diabetes
- treatment
- combination
- type
- Prior art date
Links
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title abstract 2
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 title 1
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 229960003105 metformin Drugs 0.000 abstract 3
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 abstract 3
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 abstract 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- GNZCSGYHILBXLL-UHFFFAOYSA-N n-tert-butyl-6,7-dichloro-3-methylsulfonylquinoxalin-2-amine Chemical compound ClC1=C(Cl)C=C2N=C(S(C)(=O)=O)C(NC(C)(C)C)=NC2=C1 GNZCSGYHILBXLL-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
- C07C279/24—Y being a hetero atom
- C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361753567P | 2013-01-17 | 2013-01-17 | |
| PCT/US2014/011394 WO2014113357A1 (en) | 2013-01-17 | 2014-01-14 | Combinations of a glp1r agonist and metformin and use thereof for the treatment of type 2 diabetes and other disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201591123A1 true EA201591123A1 (ru) | 2015-11-30 |
Family
ID=50030537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201591123A EA201591123A1 (ru) | 2013-01-17 | 2014-01-14 | Комбинации агониста glp1r и метформина, а также способ их применения при лечении диабета 2 типа и прочих расстройств |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20150313908A1 (enExample) |
| EP (1) | EP2945618B1 (enExample) |
| JP (1) | JP6445459B2 (enExample) |
| KR (1) | KR102165434B1 (enExample) |
| CN (1) | CN104968341B (enExample) |
| AU (1) | AU2014207748B2 (enExample) |
| CA (1) | CA2896308C (enExample) |
| EA (1) | EA201591123A1 (enExample) |
| ES (1) | ES2687083T3 (enExample) |
| IL (1) | IL239714A0 (enExample) |
| MX (1) | MX366685B (enExample) |
| SG (2) | SG10201704716XA (enExample) |
| WO (1) | WO2014113357A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3684793A1 (en) | 2017-09-22 | 2020-07-29 | Regeneron Pharmaceuticals, Inc. | Glucagon-like peptide 1 receptor agonists and uses thereof |
| WO2019217165A1 (en) * | 2018-05-08 | 2019-11-14 | Vtv Therapeutics Llc | Therapeutic uses of glp1r agonists |
| EP4130005A4 (en) * | 2020-04-01 | 2024-04-24 | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. | CRYSTALLINE FORM A OF A GLP-1 RECEPTOR AGONIST AND METHOD OF MANUFACTURING THEREOF |
| CN115315426B (zh) * | 2020-04-01 | 2023-12-12 | 杭州中美华东制药有限公司 | Glp-1受体激动剂游离碱的药学上可接受的酸式盐及其制备方法 |
| US12582651B2 (en) * | 2020-12-31 | 2026-03-24 | Dong Kook Pharm. Co., Ltd. | Pharmaceutical composition comprising tadalafil or pharmaceutically acceptable salt thereof and dutasteride or pharmaceutically acceptable salt thereof exhibiting novel dissolution rate |
| JP2025532651A (ja) | 2022-09-21 | 2025-10-01 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 肥満、糖尿病および肝機能障害を処置する方法 |
| WO2025158275A1 (en) | 2024-01-24 | 2025-07-31 | Pfizer Inc. | Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds |
| US20260199503A1 (en) | 2025-01-10 | 2026-07-16 | Regeneron Pharmaceuticals, Inc. | Glp1r agonist-tethered gdf8 antibody conjugates and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4080472A (en) | 1974-03-22 | 1978-03-21 | Societe D'etudes Et D'exploitation De Marques Et Brevets S.E.M.S. | Metformin 2-(p-chlorophenoxy)-2-methylpropionate |
| AU2006311601A1 (en) * | 2005-11-07 | 2007-05-18 | Elixir Pharmaceuticals, Inc. | Combinations of metformin and meglitinide |
| EA018225B1 (ru) * | 2008-03-07 | 2013-06-28 | Транстек Фарма, Инк. | Соединения оксадиазоантрацена для лечения диабета |
| MX2011010347A (es) * | 2009-03-30 | 2011-11-29 | Transtech Pharma Inc | Derivados sustituidos de azoantraceno, composiciones farmaceuticas y metodos de uso de los mismos. |
| WO2011031620A1 (en) | 2009-09-11 | 2011-03-17 | Transtech Pharma, Inc. | Solid compositions comprising an oxadiazoanthracene compound and methods of making and using the same |
| JP5832439B2 (ja) * | 2009-11-13 | 2015-12-16 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Ｇｌｐ−１アゴニスト、インスリン及びメチオニンを含む薬学的組成物 |
| US20110118180A1 (en) * | 2009-11-13 | 2011-05-19 | Sanofi-Aventis Deutschland Gmbh | Method of treatment of diabetes type 2 comprising add-on therapy to metformin |
| US20130040878A1 (en) * | 2011-05-13 | 2013-02-14 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for use in the treatment of diabetes type 2 patients |
-
2014
- 2014-01-14 SG SG10201704716XA patent/SG10201704716XA/en unknown
- 2014-01-14 EP EP14702159.6A patent/EP2945618B1/en active Active
- 2014-01-14 WO PCT/US2014/011394 patent/WO2014113357A1/en not_active Ceased
- 2014-01-14 AU AU2014207748A patent/AU2014207748B2/en active Active
- 2014-01-14 JP JP2015553775A patent/JP6445459B2/ja active Active
- 2014-01-14 SG SG11201504778UA patent/SG11201504778UA/en unknown
- 2014-01-14 KR KR1020157018661A patent/KR102165434B1/ko active Active
- 2014-01-14 MX MX2015008555A patent/MX366685B/es active IP Right Grant
- 2014-01-14 ES ES14702159.6T patent/ES2687083T3/es active Active
- 2014-01-14 CN CN201480004613.0A patent/CN104968341B/zh active Active
- 2014-01-14 CA CA2896308A patent/CA2896308C/en active Active
- 2014-01-14 EA EA201591123A patent/EA201591123A1/ru unknown
-
2015
- 2015-06-30 IL IL239714A patent/IL239714A0/en unknown
- 2015-07-14 US US14/799,222 patent/US20150313908A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2014207748A1 (en) | 2015-07-09 |
| MX2015008555A (es) | 2016-01-22 |
| ES2687083T3 (es) | 2018-10-23 |
| EP2945618B1 (en) | 2018-06-13 |
| SG11201504778UA (en) | 2015-07-30 |
| EP2945618A1 (en) | 2015-11-25 |
| IL239714A0 (en) | 2015-08-31 |
| KR102165434B1 (ko) | 2020-10-14 |
| AU2014207748B2 (en) | 2018-10-11 |
| MX366685B (es) | 2019-07-19 |
| WO2014113357A1 (en) | 2014-07-24 |
| JP6445459B2 (ja) | 2018-12-26 |
| KR20150104572A (ko) | 2015-09-15 |
| HK1210424A1 (en) | 2016-04-22 |
| CA2896308A1 (en) | 2014-07-24 |
| SG10201704716XA (en) | 2017-07-28 |
| US20150313908A1 (en) | 2015-11-05 |
| CN104968341B (zh) | 2020-06-09 |
| JP2016505039A (ja) | 2016-02-18 |
| CA2896308C (en) | 2021-11-09 |
| CN104968341A (zh) | 2015-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201290964A1 (ru) | Пептидные конъюгаты агонистов рецептора glp-1 и их применение | |
| EA201590715A1 (ru) | Производные эксендина-4 как двойные агонисты glp1/глюкагона | |
| EA201991345A1 (ru) | Новые соединения в качестве пептидных тройных агонистов рецепторов glp1/глюкагона/gip | |
| CY1121203T1 (el) | Θεραπευτικες χρησεις της εμπαγλιφλοζινης | |
| EA201591839A1 (ru) | Терапевтические пептиды | |
| EA201491934A1 (ru) | Аналоги глюкагоноподобного пептида-2 (glp-2) | |
| UA114710C2 (uk) | Похідне оксинтомодуліну та фармацевтична композиція для запобігання або лікування ожиріння, яка його містить | |
| EA201591727A1 (ru) | Соединения биариламида в качестве ингибиторов киназы | |
| MX2019006427A (es) | Nuevos compuestos como agonistas peptidicos de receptores de glp1/glucagon/gip. | |
| MX2015008077A (es) | Derivados de exendina-4 como agonistas dobles de glp1/gip o trigonal de glp1-gip/glucagon. | |
| EA201590058A1 (ru) | Аналоги глюкагона | |
| EA201270767A1 (ru) | Терапия на основе лигандов хемосенсорных рецепторов | |
| MX365525B (es) | Compuestos que regulan la expresión de subunidades alfa de canales de sodio regulados por voltaje en enfermedades relacionadas con epilepsia mioclónica severa de la infancia. | |
| EA201491773A1 (ru) | Лечение рассеянного склероза комбинацией лаквинимода и диметилфумарата | |
| EA201690044A1 (ru) | Модуляторы ядерного транспорта и их применение | |
| EA201590065A1 (ru) | Аналоги глюкагона, проявляющие активность на рецепторе gip | |
| EA201390506A1 (ru) | Полипептиды, которые связывают компонент с5 комплемента человека | |
| EA201400161A1 (ru) | Замещенные гетероароматические пиразолсодержащие карбоксамидные и мочевинные производные в качестве лигандов ваниллоидных рецепторов | |
| EA201590011A1 (ru) | Пептидные аналоги эксендина-4 | |
| EA201492064A1 (ru) | Варианты фактора роста фибробластов 21 | |
| MX366685B (es) | Combinaciones de un agonista de glp1r y metformina, y uso de los mismos para el tratamiento de la diabetes tipo 2 y otros trastornos. | |
| EA201490790A1 (ru) | Пептидные конъюгаты агониста рецептора гастрина и глюкагон подобного пептида 1 | |
| BR112013029256A2 (pt) | "combinações farmacêuticas para uso no tratamento de pacientes com diabetes tipo 2, método de tratamento, e usos de lixisenatida e metformina". | |
| EA201171197A1 (ru) | Замещенные производные азоантрацена, фармацевтические композиции и способы их применения | |
| EA201190209A1 (ru) | Соединения для лечения метаболических расстройств |